No Data
Unicycive Expands At-The-Market Equity Offering Program
Express News | Unicycive Therapeutics - Files Sales Agreement Prospectus to Offer up to $50 Mln of Common Stock - SEC Filing
Benchmark Co. Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Raises Target Price to $18
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Unicycive Therapeutics (UNCY)
Ramakanth Reiterates Buy on Unicycive, Sees De-Risked Path to FDA Approval With 12-Month $22 Price Target Unchanged
Guggenheim Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Cuts Target Price to $37